ATE432987T1 - Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums - Google Patents
Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstumsInfo
- Publication number
- ATE432987T1 ATE432987T1 AT07001711T AT07001711T ATE432987T1 AT E432987 T1 ATE432987 T1 AT E432987T1 AT 07001711 T AT07001711 T AT 07001711T AT 07001711 T AT07001711 T AT 07001711T AT E432987 T1 ATE432987 T1 AT E432987T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- methods
- polypeptides
- compositions
- cell growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11329698P | 1998-12-22 | 1998-12-22 | |
PCT/US1999/005028 WO1999046281A2 (en) | 1998-03-10 | 1999-03-08 | Novel polypeptides and nucleic acids encoding the same |
US13023299P | 1999-04-21 | 1999-04-21 | |
US13144599P | 1999-04-28 | 1999-04-28 | |
US13428799P | 1999-05-14 | 1999-05-14 | |
US14475899P | 1999-07-20 | 1999-07-20 | |
US14569899P | 1999-07-26 | 1999-07-26 | |
PCT/US1999/021090 WO2000015796A2 (en) | 1998-09-16 | 1999-09-15 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/021547 WO2000015797A2 (en) | 1998-09-17 | 1999-09-15 | Compositions and methods for the treatment of immune related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE432987T1 true ATE432987T1 (de) | 2009-06-15 |
Family
ID=27557838
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04007617T ATE353339T1 (de) | 1998-12-22 | 1999-12-02 | Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums |
AT07001711T ATE432987T1 (de) | 1998-12-22 | 1999-12-02 | Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04007617T ATE353339T1 (de) | 1998-12-22 | 1999-12-02 | Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1141284A2 (de) |
JP (5) | JP3993746B2 (de) |
KR (1) | KR100499600B1 (de) |
AT (2) | ATE353339T1 (de) |
AU (1) | AU768230B2 (de) |
CA (1) | CA2353799A1 (de) |
DE (2) | DE69940964D1 (de) |
DK (1) | DK1484338T3 (de) |
ES (2) | ES2327785T3 (de) |
IL (3) | IL143031A0 (de) |
MX (1) | MXPA01006330A (de) |
PT (1) | PT1484338E (de) |
WO (1) | WO2000037638A2 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999066041A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
US6392019B1 (en) | 1997-11-22 | 2002-05-21 | John Ford | Antibodies specific for EGF motif proteins |
US6808890B2 (en) | 1999-07-28 | 2004-10-26 | Nuvelo, Inc. | Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
CA2309897A1 (en) | 1997-11-22 | 1999-06-03 | Hyseq, Inc. | A novel egf motif protein obtained from a cdna library of fetal liver-spleen |
EP1251139A3 (de) * | 1998-04-08 | 2002-12-18 | Genentech, Inc. | Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure |
US6960433B1 (en) | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
BR0007556A (pt) | 1999-01-15 | 2001-10-23 | Biogen Inc | Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos |
KR100553300B1 (ko) * | 1999-03-08 | 2006-02-20 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 방법 |
JP2003505350A (ja) * | 1999-07-20 | 2003-02-12 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
KR20020062652A (ko) * | 1999-12-09 | 2002-07-26 | 상꾜 가부시키가이샤 | 고지혈증의 치료 또는 예방제의 시험방법 |
AU784349C (en) * | 2000-01-12 | 2006-09-28 | Yale University | Nogo receptor-mediated blockade of axonal growth |
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
WO2001085193A2 (en) | 2000-05-08 | 2001-11-15 | Biogen, Inc. | Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
NZ525422A (en) | 2000-10-06 | 2006-09-29 | Biogen Idec Inc | Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons |
US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
CN103536916B (zh) | 2002-04-09 | 2016-08-17 | 比奥根Ma公司 | 用于治疗tweak相关病症的方法 |
CA2391438A1 (en) * | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
EP1859277A4 (de) | 2005-02-17 | 2010-03-17 | Biogen Idec Inc | Behandlung neurologischer störungen |
JP5339901B2 (ja) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 炎症傷害の処置および評価 |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
WO2007056227A2 (en) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
WO2007117657A2 (en) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US7776573B2 (en) | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
EP2097455B1 (de) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Humanisierte anti-faktor d-antikörper |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
RU2553517C2 (ru) | 2008-05-06 | 2015-06-20 | Дженентек, Инк. | Варианты crig с созревшей аффинностью |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
KR20160042438A (ko) | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
CN114835774B (zh) * | 2022-06-29 | 2022-09-27 | 中国农业大学 | 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
US5814307A (en) * | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
US5416192A (en) * | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
US5028099A (en) * | 1990-08-08 | 1991-07-02 | Bertucco Leonard J | Trash recycling container |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) * | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
SV1999000069A (es) * | 1998-06-02 | 2000-04-11 | Lilly Co Eli | Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261 |
JP7039446B2 (ja) * | 2018-11-29 | 2022-03-22 | 株式会社東芝 | 電子装置 |
-
1999
- 1999-12-02 MX MXPA01006330A patent/MXPA01006330A/es not_active Application Discontinuation
- 1999-12-02 AT AT04007617T patent/ATE353339T1/de active
- 1999-12-02 DE DE69940964T patent/DE69940964D1/de not_active Expired - Lifetime
- 1999-12-02 AU AU17499/00A patent/AU768230B2/en not_active Expired
- 1999-12-02 IL IL14303199A patent/IL143031A0/xx not_active IP Right Cessation
- 1999-12-02 PT PT04007617T patent/PT1484338E/pt unknown
- 1999-12-02 ES ES07001711T patent/ES2327785T3/es not_active Expired - Lifetime
- 1999-12-02 AT AT07001711T patent/ATE432987T1/de not_active IP Right Cessation
- 1999-12-02 JP JP2000589692A patent/JP3993746B2/ja not_active Expired - Fee Related
- 1999-12-02 DK DK04007617T patent/DK1484338T3/da active
- 1999-12-02 WO PCT/US1999/028565 patent/WO2000037638A2/en active Search and Examination
- 1999-12-02 ES ES04007617T patent/ES2281704T3/es not_active Expired - Lifetime
- 1999-12-02 KR KR10-2001-7007850A patent/KR100499600B1/ko not_active IP Right Cessation
- 1999-12-02 DE DE69935085T patent/DE69935085T2/de not_active Expired - Lifetime
- 1999-12-02 CA CA002353799A patent/CA2353799A1/en not_active Abandoned
- 1999-12-02 EP EP99960644A patent/EP1141284A2/de not_active Withdrawn
-
2005
- 2005-03-10 JP JP2005066569A patent/JP4037876B2/ja not_active Expired - Lifetime
- 2005-03-10 JP JP2005066570A patent/JP2005237383A/ja not_active Withdrawn
-
2007
- 2007-05-24 JP JP2007138469A patent/JP2007291116A/ja active Pending
- 2007-05-24 JP JP2007138468A patent/JP2007222180A/ja active Pending
- 2007-09-20 IL IL186154A patent/IL186154A0/en unknown
- 2007-09-20 IL IL186153A patent/IL186153A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1141284A2 (de) | 2001-10-10 |
JP2005245451A (ja) | 2005-09-15 |
KR20010084882A (ko) | 2001-09-06 |
CA2353799A1 (en) | 2000-06-29 |
JP2003529317A (ja) | 2003-10-07 |
ES2327785T3 (es) | 2009-11-03 |
ES2281704T3 (es) | 2007-10-01 |
AU768230B2 (en) | 2003-12-04 |
DK1484338T3 (da) | 2007-06-11 |
ATE353339T1 (de) | 2007-02-15 |
WO2000037638A3 (en) | 2000-11-09 |
JP2007222180A (ja) | 2007-09-06 |
IL186153A0 (en) | 2008-01-20 |
JP2005237383A (ja) | 2005-09-08 |
DE69935085T2 (de) | 2007-08-23 |
AU1749900A (en) | 2000-07-12 |
JP2007291116A (ja) | 2007-11-08 |
JP3993746B2 (ja) | 2007-10-17 |
PT1484338E (pt) | 2007-05-31 |
IL186154A0 (en) | 2008-01-20 |
MXPA01006330A (es) | 2002-07-02 |
JP4037876B2 (ja) | 2008-01-23 |
DE69935085D1 (de) | 2007-03-22 |
IL143031A0 (en) | 2002-04-21 |
DE69940964D1 (de) | 2009-07-16 |
KR100499600B1 (ko) | 2005-07-07 |
WO2000037638A2 (en) | 2000-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE432987T1 (de) | Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums | |
ATE357518T1 (de) | Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums | |
ATE408419T1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors | |
ATE380195T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
HK1114636A1 (en) | 1l-17 homologous polypeptides and therapeutic uses thereof | |
IL193149A (en) | Anti il-17c antibody and therapeutic compositions comprising same | |
ATE397063T1 (de) | Fibroblasten-wachstumsfaktor-19 | |
ATE444971T1 (de) | Zusammensetzungen und verfahren für die tumor- behandlung | |
DE69940681D1 (de) | Zusammensetzung und Verfahren zur Diagnose von Tumoren | |
WO2000032778A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
WO2001049715A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
EP2075335A3 (de) | Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums | |
EP1870464A3 (de) | Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums | |
KR100515858B1 (en) | PRO617 Polypeptides | |
WO2000007545A3 (en) | Apoptosis proteins | |
KR100515857B1 (en) | PRO792 Polypeptides | |
KR100515855B1 (en) | PRO351 Polypeptides | |
KR100515856B1 (en) | PRO618 Polypeptides | |
DK1249491T3 (da) | Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |